Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

By afschroeder • April 1, 2026

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma. Future Oncol. 2026 Mar 31:1-19. doi: 10.1080/14796694.2026.2643481. Epub ahead of print. PMID: 41914670.

Tags: binimetinib, BRAF V600, Encorafenib, Hematology/Oncology, LOGIC 2, melanoma, plain language summary, Publications, third drug

Related Posts

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

Hecht JR, Molina JR, Liechty K, Welling TH, Grierson PM, Patel SP, Kirtane K, Morelli MP, Locke FL, Maloney DG, Punekar SR, Nikiforow S, Lin[...]

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao[...]

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder[...]